Patients receiving any statin except pravastatin or rosuvastatin
The patient requires statin therapy. Patients who are taking a statin and are considered appropriate to discontinue treatment, must discontinue the statin at least 5 days prior to starting study therapy.
History of allergic reaction or intolerance to statin treatment
Currently receiving statin therapy or have received any statin therapy within the last 3 months
Patients must be off all \statin\ drugs for ?2 weeks prior to initiation of therapy.
Use of statin drugs or other medications known to associate with rhabdomyolysis; these drugs must be discontinued at enrollment
Statin use in the last 6 months
Patients who have been on a statin other than simvastatin within 2 weeks of starting treatment on current study; these include atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, and rosuvastatin; if patient is on statin, will need to stop treatment 2 weeks prior to starting treatment on study
Patients currently treated with metformin or a statin or who have been treated with metformin or a statin in the past 6 months are ineligible for this study
Ongoing anticoagulant, statin and/or anti-platelet therapy
Current use of a statin
Diagnosis of cardiovascular disease (CVD) with or without current statin use
The allogeneic PBSC donor has a contraindication to statin treatment
DONOR: Current use of statin drug
Statin use or statin use is indicated based on guidelines
Prior or current use of statin medication
The allogeneic PBSC donor has a contraindication to statin treatment
Current use of statin medication or statin use within 12 months of screen 1 visit
Current use of statin therapy
Are currently taking a statin or have taken a statin in the past 6 months or have a history of an allergic reaction or intolerance at any time to a statin